MapLight Therapeutics, Inc. MPLT

Updated: 8 Aug 2026

NASDAQ | Biotech | Biotechnology and neuroscience

No signal published yet

We already track MapLight Therapeutics and collect the news. No signal is published yet — follow the company free and we will email you when that changes, or run a quick check now.

Follow MapLight Therapeutics free Follow free

Email when we publish a signal or something material happens · Sunday weekly brief

No card · No time limit on free tier · Upgrade when you need more

Free
No email, no account, no signup.
Exchange
NASDAQ
Type
Biotech
Sector
Biotechnology and neuroscience
We're already tracking MapLight Therapeutics, Inc. — here are the latest events we've registered

Recent News

  • On July 27, 2026, MapLight reported results from the Phase 2 ZEPHYR trial evaluating ML-007C-MA in schizophrenia. The trial met its primary endpoint for the twice-daily dosing regimen with a statistically significant improvement over placebo, whereas the once-daily arm missed statistical significance. Despite reaching the primary endpoint, the stock experienced a steep drop as investors weighed the efficacy results against competing approved therapies.

What Firelda Watch includes for MapLight Therapeutics, Inc.

Add the company to your watchlist and get all of this automatically.

  • Free: 3 companies on your watchlist
  • Change history and monitoring for every company you follow
  • Sunday weekly brief — a short weekly roundup
  • Watch/Ultra: same-day email when something material happens
Want to see what a finished analysis looks like?
View a sample analysis
This is a real Firelda analysis. Your analysis of MapLight Therapeutics, Inc. will be delivered in the same format.

Sample analyses in the same sector

Sample full analysis — same format your watchlist gets

Hansa Biopharma AB (publ)
HNSA
HOLD
Bioarctic
BIOA B
BUY
Sprint Bioscience AB (publ)
SPRINT
NEUTRAL
Xbrane Biopharma AB (publ)
XBRANE
HOLD
SynAct Pharma AB
SYNACT
HOLD

Biotech

More companies in this sector

Want to follow MapLight Therapeutics, Inc.? Create a free account — 3 companies, change history, weekly brief, and email when the picture changes.

Follow MapLight Therapeutics free Follow free

Email when we publish a signal or something material happens · Sunday weekly brief

No card · No time limit on free tier · Upgrade when you need more

MapLight Therapeutics, Inc. MPLT
MapLight Therapeutics — follow and we'll monitor it
Follow MapLight Therapeutics free Follow free
Firelda provides general information and analysis, not personal investment advice. Content does not consider your financial situation or goals. Investments can rise and fall in value. Always do your own research.